The review, conducted in accordance with the PRISMA 2020 reporting guidelines, searched PubMed, Web of Science, Cochrane CENTRAL, and Google Scholar for peer-reviewed studies published between 2015 and 2025. The team led by Razan Suliman Alhumayed included randomized trials and observational studies reporting weight-related outcomes with either oral or subcutaneous semaglutide. Because the included studies differed substantially in population, formulation, dose, indication, comparator, design, and follow-up duration, the authors chose a narrative synthesis rather than quantitative pooling, a decision that shapes how their conclusions should be read.

The headline finding concerns the obesity-focused trials that excluded diabetes. In these studies, once-weekly subcutaneous semaglutide at the 2.4-milligram dose, the regimen approved specifically for chronic weight management, generally produced mean weight reductions of approximately 14 to 17 percent over 68 weeks. For a patient weighing 100 kilograms, that translates to a loss of roughly 14 to 17 kilograms, a magnitude that rivals some bariatric surgical outcomes and far exceeds what lifestyle intervention alone typically achieves. A trial testing a higher 7.2-milligram regimen produced even greater weight loss, hinting at a dose-response relationship that could define the next generation of obesity pharmacotherapy.

The biology behind these numbers is central to understanding why semaglutide behaves the way it does. As a long-acting glucagon-like peptide-1 receptor agonist, the drug reduces appetite and energy intake through both central and gastrointestinal mechanisms, mimicking a gut hormone that signals satiety to the brain and slows gastric emptying. Available in subcutaneous and oral formulations, semaglutide is used across two major indications, obesity and type 2 diabetes mellitus, with dosing that differs by formulation and indication. That dual identity is precisely why the review’s authors insist the evidence must be interpreted in a population-specific way.

In studies of people with type 2 diabetes, the weight-loss picture changes noticeably. Reductions in body weight were smaller in the diabetes trials than in the obesity-focused studies, but they were accompanied by clinically important improvements in HbA1c, the standard measure of long-term blood glucose control. This distinction matters enormously for clinical practice. A patient with diabetes starting semaglutide should expect meaningful metabolic benefits alongside more modest weight changes, while a patient without diabetes on the higher obesity dose can anticipate the larger reductions. The review also separated out the oral formulation studies, which primarily enrolled participants with type 2 diabetes, and interpreted them distinctly from the obesity-dose subcutaneous trials rather than blending the evidence together.

Safety findings form the other half of the story, and they are unlikely to surprise clinicians who have watched GLP-1 prescriptions soar. Gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were the most frequent tolerability issue across the included studies, and their frequency tended to increase during dose escalation and with higher cumulative exposure. This pattern reinforces the importance of gradual titration schedules, which are designed to let the body adapt before patients reach the maintenance dose. For most patients these effects are manageable, but they remain the leading reason people struggle with the treatment in its early months.

Beyond the digestive system, the review flagged several less common but clinically significant signals. Gallbladder events, treatment discontinuation, and a diabetic retinopathy signal observed in the SUSTAIN-6 cardiovascular outcomes trial all warrant careful, population-specific interpretation. The retinopathy finding, in particular, has implications for patients with diabetes and pre-existing eye disease, suggesting that clinicians should monitor vision in vulnerable groups when initiating therapy. None of these signals outweighs the drug’s demonstrated benefits, but they complicate the simple narrative of a miracle weight-loss injection that has dominated social media and popular coverage.

Perhaps the most sobering finding for the millions of people now taking or considering the drug concerns what happens when treatment stops. Weight regain after discontinuation was substantial in the withdrawal and extension studies included in the review. This observation underscores a biological reality that obesity specialists have long emphasized: obesity is a chronic disease, and pharmacotherapy that suppresses appetite works only while the drug is on board. Once treatment ends, the physiological drivers of weight regain reassert themselves, often erasing hard-won losses. The finding has significant implications for health systems and insurers weighing the cost of lifelong therapy against the consequences of relapse.

The review’s authors are careful about the limits of their own work. Because no quantitative pooling was performed, their conclusions are descriptive and should be interpreted cautiously. The strongest weight-loss evidence derives from obesity-focused subcutaneous trials, while findings from diabetes studies, cardiovascular outcome trials, oral formulation studies, and observational cohorts provide complementary but not directly interchangeable evidence. In an era when headlines often flatten these distinctions, the review serves as a reminder that the answer to how much weight a patient might lose depends heavily on who the patient is, which formulation they take, and at what dose.

What emerges from this comprehensive synthesis is a portrait of a genuinely transformative but imperfect therapy. Semaglutide is associated with clinically meaningful weight reduction, and for adults with obesity the 14 to 17 percent average losses achieved with the 2.4-milligram weekly injection represent a genuine turning point in obesity medicine. Yet the magnitude of benefit and the safety profile vary by population, formulation, dose, indication, and study design, and the substantial weight regain after discontinuation tempers any expectation of a permanent pharmacological fix. As prescriptions continue to climb worldwide, this review offers clinicians and patients alike a rigorously assembled evidence base for setting realistic expectations, managing side effects proactively, and planning for the long-term realities of chronic weight management.

Subject of Research: Efficacy and safety of semaglutide for weight loss in adults with overweight or obesity

Article Title: Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis

Article References: Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis. (n.d.). https://doi.org/10.1186/s12902-026-02641-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02641-z

Keywords: semaglutide, obesity, weight loss, GLP-1 receptor agonists, systematic review, type 2 diabetes, gastrointestinal side effects, weight regain, subcutaneous injection, oral semaglutide, HbA1c, drug safety

The clinical backdrop is well established. GLP-1 receptor agonists have transformed the pharmacological treatment of obesity, producing weight reductions that were once achievable only through bariatric surgery for many patients. These drugs mimic the incretin hormone GLP-1, slowing gastric emptying, enhancing satiety after meals, and acting on appetite-regulating circuits in the brain. Yet discontinuation is remarkably common. Cost is a major driver, since many insurers do not cover anti-obesity medications or impose restrictive prior-authorization requirements. Side effects such as nausea, vomiting, and gastrointestinal discomfort lead some patients to quit. Others simply prefer not to remain on long-term injections. Whatever the reason, the result is frequently the same: weight returns, often quickly, as appetite and eating behavior revert toward pre-treatment patterns.

That rebound is not merely a cosmetic disappointment. Regained weight can erode the metabolic benefits of the initial loss, including improvements in blood pressure, glycemic control, and lipid profiles. Clinicians have therefore been searching for practical, scalable strategies to help patients hold on to their gains after stopping the drug. The new trial was designed as a pilot to test whether two very different forms of support—a digital wellness application and medically tailored meals—could slow the regain compared with ordinary follow-up care.

The study enrolled 39 adults who had previously lost weight with GLP-1 therapy and randomized them at the time of cessation into one of three groups. The first received usual care, essentially standard follow-up without any structured intervention. The second received access to a digital wellness application, a tool designed to support healthy eating, activity, and self-monitoring behaviors. The third received medically tailored meals, an approach rooted in the Food is Medicine movement, in which prepared meals designed by nutrition professionals are delivered to support dietary needs directly. Each intervention continued for four months after the medication was stopped, a window in which regain typically begins.

The headline numbers are dramatic, even allowing for the small sample size. Over the four-month follow-up, participants in the usual care group gained an estimated 10.75 percent of their body weight on average. By contrast, those using the wellness application gained an estimated 3.60 percent, and those receiving medically tailored meals gained an estimated 3.58 percent. In other words, both structured interventions were associated with roughly a two-thirds reduction in early weight regain relative to control. For a field in which even modest attenuation of rebound would be considered meaningful, the magnitude of that difference is notable.

The secondary measures told a more nuanced story. Surveys administered during the trial found no statistically significant differences between groups in diet quality, perceived health, adherence, or satisfaction, although some estimates hinted at trends that may have favored the wellness application. The authors are careful not to overinterpret these signals; with only 39 participants, the study was not powered to detect small differences in self-reported outcomes, and the absence of significance does not mean the interventions had no effect on these measures. It does, however, suggest that the weight outcomes were not simply a reflection of participants in the intervention groups feeling better or reporting healthier habits—the objective weight data carry the primary signal.

What might explain the mechanism? Medically tailored meals remove a substantial share of the decision-making burden from eating. When GLP-1 drugs are withdrawn, the pharmacological suppression of appetite disappears, and hunger hormones such as ghrelin can rebound while satiety signaling weakens. In that environment, having nutritionally controlled meals delivered directly may act as an external scaffold, substituting structure for the lost drug effect. The wellness application, meanwhile, may work through behavioral self-monitoring, feedback, and goal reinforcement—tools with a long track record in weight maintenance research, though results there have historically been mixed. Both interventions, in different ways, replace some of the external regulation the medication provided with environmental or behavioral regulation.

The corresponding author, Kelseanna Hollis-Hansen, PhD, MPH, of the Tufts University Food is Medicine Institute, framed the stakes in human terms. People invest significant time and effort in improving their health and achieving weight loss, she noted, and the field needs evidence-based strategies to support them if and when they discontinue GLP-1 medication, so they can maintain those gains and continue building long-term health, vitality, and well-being. Her comment underscores a growing consensus among obesity researchers: these medications should be understood not as short-term courses but as chronic-disease therapies, and the transition off them deserves the same clinical attention as the initiation.

Important caveats temper the excitement. This was a pilot trial with a small number of participants and a short follow-up period of only four months, so the findings should be treated as hypothesis-generating rather than practice-changing. The estimated weight changes carry wide uncertainty at this sample size, and it remains unknown whether the early differences would persist over one or two years, which is the timescale on which weight maintenance ultimately succeeds or fails. The trial also did not compare the two interventions head to head in a way that could establish superiority, and both performed almost identically on the primary outcome, leaving open the question of which is more practical, cost-effective, or scalable for real-world health systems.

Even so, the study arrives at a moment of intense public and scientific interest in the aftermath of GLP-1 therapy. As prescriptions have surged, so has the population of people stopping the drugs, whether because of supply disruptions, cost, or personal choice. The trial’s central message is that discontinuation does not have to mean abandonment. Structured, relatively low-burden support—whether a well-designed app or a box of medically tailored meals—may buy patients precious time to consolidate behavioral habits before appetite fully rebounds. Larger randomized trials will be needed to confirm the effect, identify which patients benefit most, and determine how long the support should last. But the pilot suggests that the window immediately after stopping GLP-1 therapy is a critical, and potentially modifiable, period—one in which the right support could mean the difference between keeping hard-won health gains and watching them slip away.

Subject of Research: Preventing weight regain after discontinuation of GLP-1 receptor agonist therapy for obesity

Article Title: What’s the best way to prevent weight regain after GLP 1 therapy discontinuation?

Article References: What’s the best way to prevent weight regain after GLP 1 therapy discontinuation?. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: GLP-1 receptor agonists, obesity, weight regain, weight maintenance, medically tailored meals, digital wellness app, randomized controlled trial, Food is Medicine, Tufts University, Obesity Science & Practice, discontinuation, pilot study

The Perspective, published in the JAMA Network on 1 October 2026, urges clinicians and health systems to build multimodal management of obesity that extends well beyond pharmacological treatment. According to the authors, effective care must integrate screening, early management, and intensive behavioral therapy across the entire life course. The argument is not a rejection of GLP-1 therapies, which the authors implicitly recognize as a powerful new tool, but a warning against treating them as a complete solution. Obesity, they contend, requires the same kind of comprehensive, long-term clinical architecture that other chronic diseases have demanded for decades.

The scientific rationale for this position rests on the biology of obesity itself. Body fat mass is regulated by a network of hormonal, neural, and behavioral feedback loops centered on the hypothalamus, the gut, adipose tissue, and the reward circuits of the brain. GLP-1 receptor agonists intervene at one crucial node of this network: they mimic an incretin hormone released after meals, slowing gastric emptying, enhancing satiety, and reducing appetite through both hypothalamic and higher-order neural pathways. Newer agents add glucose-dependent insulinotropic polypeptide activity, further improving metabolic outcomes. The results in randomized trials have been striking, with double-digit percentage losses of body weight now achievable pharmacologically for the first time.

But the same biology explains why medication alone is structurally insufficient. Obesity is characterized by adaptations in energy homeostasis that defend body fat stores. When caloric intake falls, whether through diet, surgery, or drugs, compensatory mechanisms increase hunger, reduce satiation, and lower resting energy expenditure. Trials of GLP-1 therapies have shown that discontinuation is typically followed by substantial weight regain, a pattern consistent with the rebound observed after intensive lifestyle interventions and bariatric surgery. The disease process persists beneath the treatment effect, which is why the Perspective frames pharmacotherapy as one component of a durable management strategy rather than a cure.

This is where the multimodal model becomes central. The authors call for systematic screening so that obesity and its early metabolic disturbances are identified before they progress to established comorbidities such as type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease, obstructive sleep apnea, and several obesity-associated cancers. Early management, in their framing, means intervening at the stage when lifestyle change and modest pharmacological support can alter trajectory most effectively, rather than waiting until advanced disease leaves fewer options. Screening also carries an equity dimension, because obesity prevalence and access to care vary sharply across socioeconomic groups and regions, and late diagnosis tends to concentrate in populations with the fewest resources.

Intensive behavioral therapy forms the third pillar. Decades of research, including the landmark Diabetes Prevention Program, have established that structured programs combining dietary change, physical activity, and behavior modification can produce meaningful weight loss and reduce progression to type 2 diabetes, even before modern drugs existed. The Perspective argues that these interventions should not be displaced by pharmacotherapy but combined with it. Behavioral support addresses the skills, environment, and psychological factors that determine whether initial weight loss is maintained, and it remains the component of care that patients continue to control after any prescription ends. In a health system organized around multimodal care, a patient beginning a GLP-1 medication would simultaneously receive nutritional counseling, physical activity guidance, and structured follow-up designed to outlast the treatment period.

The life-course emphasis of the Perspective adds a further layer of urgency. Obesity develops through interactions of genetics, early-life nutrition, environment, and behavior, and its consequences accumulate across decades. Adiposity established in childhood and adolescence tracks strongly into adulthood and raises the lifetime burden of cardiometabolic disease. At the other end of the age spectrum, older adults face the dual challenge of excess fat mass and loss of lean muscle, making weight management strategies that preserve muscle and bone particularly important. A therapy-centered model that ignores these developmental windows, the authors suggest, will systematically miss the points of maximum leverage.

The comorbidity dimension is equally consequential. Obesity rarely travels alone; it clusters with hypertension, dyslipidemia, insulin resistance, chronic kidney disease, and mental health conditions including depression, and it multiplies the clinical complexity of each. Interestingly, some GLP-1 and related agents have shown cardiovascular and renal benefits in dedicated outcome trials, suggesting that the pharmacological era may deliver dividends beyond weight itself. Even so, the Perspective’s central claim stands: managing the comorbidities of obesity requires coordinated clinical attention to each condition, integrated screening protocols, and care pathways that treat the patient as a whole rather than a prescription target. Multimodal care, in this vision, is as much about health-system design as about individual treatment choices.

The timing of the argument reflects a real-world inflection point. Health systems are currently absorbing the consequences of explosive GLP-1 demand: shortages, questions about lifelong therapy costs, insurance coverage debates, and a growing population of patients who begin these drugs without any accompanying behavioral or nutritional support. Clinical guidelines from major professional societies already recommend that pharmacotherapy be combined with lifestyle intervention, but implementation has lagged, driven by cost, workforce limitations, and fragmented reimbursement. The Perspective effectively functions as a policy signal, urging that the infrastructure of obesity care, from primary care screening to structured behavioral programs, be built in parallel with drug access rather than as an afterthought.

What emerges from the JAMA Perspective is a pragmatic synthesis rather than a rejection of the pharmacological revolution. GLP-1 therapies have removed one of the most discouraging barriers in obesity medicine, the limited efficacy of available drugs, and they deserve a central place in treatment. But the disease they treat is chronic, adaptive, and woven into behavior and environment across a lifetime. The authors’ prescription is correspondingly broad: screen early, intervene early, deliver intensive behavioral therapy, combine these elements with medication where appropriate, and sustain care across the life course. If health systems follow that blueprint, the GLP-1 era may be remembered not as the moment obesity was medicated, but as the moment its comprehensive management finally became possible.

Subject of Research: Multimodal clinical management of obesity and its comorbidities in the era of GLP-1 receptor agonist therapies

Article Title: Building effective multimodal care for obesity and comorbidities in the GLP-1 therapy era

Article References: Building effective multimodal care for obesity and comorbidities in the GLP-1 therapy era. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: obesity, GLP-1 receptor agonists, multimodal care, behavioral therapy, comorbidities, screening, JAMA, World Health Organization, chronic disease, weight regain, life course, health systems

The clinical stakes could hardly be higher. GLP-1 receptor agonists, which mimic the gut hormone glucagon-like peptide-1 to suppress appetite and improve metabolic control, are not permanent cures for obesity. According to research cited by the UTHealth Houston team, roughly 30 percent of patients stop taking the medications within six months, and about 50 percent discontinue within a year. The consequences of stopping are stark: most individuals regain more than 60 percent of the weight they lost within a single year of discontinuation. That rebound is not merely cosmetic. Along with the returning pounds come the return of serious health risks, including type 2 diabetes and cardiovascular complications, erasing many of the therapeutic gains that made these drugs so transformative in the first place.

What intrigues scientists most is that the rebound is not uniform. Not everyone regains weight at the same rate, and not everyone sees their metabolic health deteriorate equally after stopping treatment. This variability has led researchers to hypothesize that the body may retain a kind of metabolic memory, molecular traces of the medication or of the previous weight loss that continue to influence how metabolism behaves long after the last injection. If such memory exists and can be measured, it could fundamentally change how doctors prescribe these drugs, helping them identify in advance which patients are genetically predisposed to regain weight and which might safely taper off therapy.

At the heart of the new grant is the phenomenon of weight cycling, the repeated loss and regain of body weight associated with stopping and restarting any weight loss strategy, whether pharmacological, dietary, or surgical. The rebound effect is driven by complex physiological adaptations that evolution engineered to defend body weight: appetite surges, energy expenditure drops, and hormonal shifts conspire to restore lost fat stores. Weight cycling can also exact its own toll, contributing to muscle loss, a slowing of resting metabolism, and strain on the cardiometabolic system. Understanding the genetic and molecular underpinnings of this cycle, the researchers argue, is essential to breaking it.

The study itself is a rigorously designed double-blind randomized trial involving 100 participants with obesity drawn from the Border Health Research Cohort. Each participant will receive semaglutide, one of the most widely prescribed GLP-1 receptor agonists, for six months. After that initial treatment period, half of the group will be randomly selected to discontinue the medication while the other half will remain on GLP-1 therapy. This design allows the investigators to compare, under controlled and blinded conditions, what happens in the bodies of people who stop the drug versus those who continue it, isolating the biological consequences of withdrawal from the natural variability of weight and metabolism.

Researchers will analyze genetic markers in both groups, focusing on markers related to insulin metabolism, energy expenditure, appetite hormones, and body composition. These markers could serve as predictors of therapeutic durability, telling clinicians early on whether a given patient is likely to maintain the benefits of treatment after stopping. The population under study is also significant. The Border Health Research Center, established in 2003, specializes in studying risk factors for obesity, diabetes, and related complications among Americans of Mexican descent living in the Lower Rio Grande Valley, a community that has been historically underrepresented in metabolic research despite carrying a substantial burden of cardiometabolic disease.

To capture what happens to the body at every stage of stopping and starting GLP-1 medications, the team will take small fat tissue and blood samples and examine how gene activity changes after the drug is withdrawn. They will measure circulating molecules, gene expression patterns, and immune signals to track how energy use and metabolism shift in the absence of the medication. Participants will also receive a standardized test meal, allowing the researchers to measure in real time how blood sugar, insulin response, and appetite behave once the drug’s pharmacological grip is released. These dynamic measurements go far beyond what a simple scale can reveal, offering a molecular-level view of the rebound process as it unfolds.

Throughout the trial, participants will undergo whole-body scans to assess changes in body composition, distinguishing fat loss from muscle loss, along with breathing tests that measure resting calorie burn, a direct readout of metabolic rate. Detailed surveys will track diet and exercise habits, ensuring that behavioral factors can be accounted for when interpreting the biological data. Together, these measurements will build a comprehensive picture of how discontinuation reshapes metabolism, from the activity of individual genes in fat tissue to the whole-body balance of energy intake and expenditure.

Co-principal investigator Joseph B. McCormick, MD, professor of epidemiology at the School of Public Health, who holds the James H. Steele, DVM, Professorship, emphasized the clinical significance of the problem. According to McCormick, weight regain after GLP-1 receptor agonist discontinuation is a significant clinical challenge, and this randomized, blinded trial will help uncover why some people regain weight while others do not, including the possibility of a metabolic memory of the initial treatment. He noted that because controlled molecular studies of GLP-1 receptor agonist exposure and withdrawal have not previously been reported, the work could identify new drug targets and predictive biomarkers of therapeutic durability in an understudied population. In other words, the trial may be the first of its kind to watch, molecule by molecule, what happens when these drugs are withdrawn under controlled conditions.

By pinpointing the molecular changes that occur in fat tissue and blood after discontinuation, the researchers hope to uncover new biological targets for future treatments that could prevent weight rebound altogether. The ultimate goal is to help doctors preserve the long-term health benefits of weight loss even after medication stops, transforming GLP-1 therapy from a treatment that works only as long as it is taken into one whose benefits can be understood, predicted, and perhaps extended. For the millions of patients who have experienced the discouragement of regaining hard-lost weight, and for the clinicians trying to guide them, the answers emerging from this Houston-led trial could mark the beginning of a more durable era in obesity medicine.

Subject of Research: Genetic and molecular determinants of weight regain after discontinuation of GLP-1 receptor agonist therapy

Article Title: NIH awards $4 million grant to study GLP-1 weight regain

Article References: NIH awards $4 million grant to study GLP-1 weight regain. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: GLP-1 receptor agonists, weight regain, obesity, semaglutide, genetic markers, metabolic memory, weight cycling, NIH grant, UTHealth Houston, endocrinology, randomized trial, cardiometabolic health

The scale of that mortality burden helps explain why ESE has chosen to invest in a focused, small-cohort training programme rather than relying on general continuing medical education. Obesity is no longer viewed simply as a consequence of lifestyle choices; it is increasingly understood as a chronic, relapsing, multifactorial endocrine disease involving dysregulation of appetite pathways, adipose tissue function, insulin signalling and reproductive hormones. As the scientific understanding of obesity continues to evolve, endocrinologists play an essential role in its prevention, diagnosis and management. The new School has been developed to complement existing obesity education across Europe, with a specific and deliberate focus on obesity as an endocrine disease, an angle that distinguishes it from broader weight-management courses aimed at general practitioners or public health specialists.

The three-day, in-person programme will cover both the clinical and mechanistic aspects of obesity, bringing together leading experts from across Europe to explore the latest developments in this rapidly evolving field. According to Gregory Kaltsas, chair of the ESE Education Committee, the format is built around interactive learning, case-based discussions and networking opportunities, so that participants gain valuable scientific knowledge while building relationships that support future collaboration and research. The curriculum reads like a survey of the field’s current frontiers. Topics include the genetics of obesity, adipose tissue biology and function, food noise, weight regain, treatments, new frontiers in the field, and the intersections between obesity and endocrinology across the life course, including puberty, menopause and polyendocrine metabolic ovarian syndrome.

Several of those topics deserve closer attention, because they map directly onto the most active areas of obesity science today. The genetics of obesity, for instance, has been transformed by large-scale genome-wide association studies that have identified hundreds of genetic variants influencing body mass index, many of which act through the central nervous system’s regulation of hunger and satiety. Understanding monogenic and polygenic forms of obesity allows clinicians to stratify patients, anticipate disease trajectories and, in a growing number of cases, select targeted therapies. Adipose tissue biology, meanwhile, has shifted from viewing fat as a passive energy store to recognising it as a dynamic endocrine organ that secretes hormones such as leptin and adiponectin, modulates inflammation and determines metabolic health outcomes in ways that vary dramatically between individuals of the same body weight.

The inclusion of food noise and weight regain on the syllabus reflects two of the most discussed clinical phenomena of the current treatment era. Food noise, a term popularised by patients describing persistent intrusive thoughts about food, has become a focal point for research into how brain reward and hunger circuits drive eating behaviour, and how modern pharmacotherapies appear to quieten it. Weight regain, conversely, remains the central challenge of long-term obesity management: physiological adaptations, including reduced resting energy expenditure and elevated appetite signalling, conspire to restore lost weight after almost every intervention, whether dietary, surgical or pharmacological. Teaching early-career clinicians why regain happens, and how emerging combination therapies might counteract it, is precisely the kind of mechanistic training the School intends to provide.

The target audience is equally specific. The School is aimed at Fellows and early-career clinicians with experience in the obesity field who are seeking to further specialise in this area of endocrinology. Participation is application-based and limited to a maximum of 25 fellows, a deliberately small number intended to create a highly interactive learning environment in which every attendee can engage directly with faculty. All successful applicants will also be invited to present a clinical case report during dedicated programme sessions, an element that transforms passive attendance into active scholarly contribution and gives young clinicians experience in presenting complex, real-world patient scenarios to senior experts.

The scientific calibre of the faculty is a central part of the offering. The Scientific Programme Committee comprises eight of Europe’s leading endocrinologists with a specialism in obesity: Blandine Gatta Cherifi (France), Karine Clément (France), Daniela Cota (France), Maeve Durkan (Ireland), Melania Manco (Italy), Uberto Pagotto (Italy), Kristina Saravinosvka (Serbia) and Liesbeth van Rossum (Netherlands). The group spans several of the continent’s most productive obesity research centres, and its multinational composition signals ESE’s intention to make the School a genuinely European platform rather than a national or single-centre initiative. For applicants, the prospect of three days of close contact with this level of expertise is likely to be the strongest draw.

Daniela Cota, speaking as a representative of the Scientific Programme Committee, framed the launch as an investment in the specialty’s future. She described obesity as one of the most pressing health challenges of our time and emphasised that endocrinologists have a vital role to play in improving outcomes for people living with the disease. Through the launch of the School, she said, ESE is supporting talented early-career clinicians and researchers to develop the expertise, networks and confidence needed to lead progress in the field. She added that the new School reflects ESE’s commitment to advancing endocrine science and clinical care while ensuring members have access to high-quality education in areas of growing importance, and expressed enthusiasm about welcoming applications for the inaugural event and supporting a new generation of obesity specialists.

The practical arrangements are designed to lower barriers to participation. Successful applicants will receive access to the full educational programme, accommodation and catering during the event, while a limited number of meeting grants will be available for eligible ESE members from low- and middle-income countries, a provision aimed at ensuring the School draws talent from across the entire WHO European Region rather than only its wealthier western half. The venue, Sabàtic Gavà Mar in Barcelona, a Tribute Portfolio Hotel, is conveniently located near Barcelona Airport, enabling participation from attendees across Europe and beyond with minimal travel friction, an apparently small logistical detail that matters considerably for a three-day intensive course drawing an international cohort.

The application window is already open and closes on 1 October 2026, giving prospective fellows a defined period to prepare their submissions. Applicants should submit a covering letter outlining their interest in attending, together with a curriculum vitae, a publication list and an optional supporting letter from a supervisor. Further information and application details are available on the ESE event website. For a field in which new drug classes, genetic insights and neuroscientific models of appetite are reshaping clinical practice at unprecedented speed, the arrival of a dedicated European training school for obesity endocrinology marks a significant institutional commitment, and the 25 fellows selected for the Barcelona inaugural will be among the first clinicians trained specifically to lead that transformation.

Subject of Research: A new European training school for early-career specialists in obesity endocrinology

Article Title: European Society of Endocrinology launches new Obesity and Endocrinology School for 2027

Article References: European Society of Endocrinology launches new Obesity and Endocrinology School for 2027. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: obesity, endocrinology, European Society of Endocrinology, medical education, Barcelona, adipose tissue, weight regain, food noise, genetics of obesity, early-career clinicians, fellowship, WHO European Region

The authors ground their argument in a conceptual shift that has been gathering force since the Lancet Commission on the Definition of Clinical Obesity published its diagnostic framework in 2025. That commission drew a sharp line between preclinical obesity, a state of elevated risk in which organs still function normally, and clinical obesity, an established disease in which excess adiposity has begun to damage organs or limit physical function. This is not semantic hair-splitting. The distinction determines who needs what, and when. A patient with preclinical obesity may be well served by lifestyle support and, in some cases, medication to prevent progression. A patient with clinical obesity, whose joints, liver, heart, or metabolism are already failing under the burden of diseased fat tissue, may need interventions powerful enough to reverse established organ dysfunction, and quickly.

Cohen and his colleagues contend that failing to make this distinction carries four concrete harms. First, clinicians may delay escalating treatment for patients with clinical disease, the very group that benefits most from definitive therapy, while they wait to see whether a drug trial will succeed. Second, patients at the preclinical stage risk over-medicalization, receiving intensive and costly interventions they do not yet require. Third, when clinical trials enroll undifferentiated populations that mix these two states, the measured treatment effects become diluted, obscuring which therapy truly helps whom. Fourth, health systems with finite resources end up spending them inefficiently, funding interventions for people who would have done well with less while rationing them from people whose disease demands more. The positioning of surgery, in other words, is not an organizational detail but a question with direct clinical and economic stakes.

So what does the evidence say surgery can still deliver? The authors describe metabolic bariatric surgery as remaining among the most durable interventions available for clinical obesity. Operations such as sleeve gastrectomy and gastric bypass do more than restrict intake; they alter gut hormone signaling, appetite regulation, and glucose metabolism in ways that reduce adiposity, improve organ function, and, in a substantial fraction of patients, drive remission of obesity-related conditions including type 2 diabetes. Where a daily injectable drug works only for as long as it is taken, a surgical intervention produces anatomical and hormonal changes that persist. Long-term observational cohorts and randomized trials have documented weight loss and cardiometabolic benefit extending well beyond a decade after operation, a horizon no current pharmacotherapy has matched in head-to-head comparison.

The safety picture has also changed almost beyond recognition. The perspective emphasizes that over the past three decades surgical practice has evolved through technical refinement, standardized protocols, and systematic perioperative optimization. Contemporary bariatric surgery, supported by randomized clinical trials and mature long-term observational datasets, is described by the authors as a very safe therapeutic option for patients with advanced obesity and complex metabolic disease. Mortality rates for modern procedures are comparable to those of routine general surgery such as gallbladder removal, a statistic that surprises many clinicians whose mental image of the field was formed in an earlier era. The operations themselves have been refined laparoscopically and, increasingly, robotically, with shorter hospital stays and fewer complications than the open procedures of the 1990s.

Yet the authors do not dismiss the new pharmacotherapy; quite the opposite. Their argument is that glucagon-like peptide-1 receptor agonists and related agents are legitimate, powerful tools that belong inside a multimodal treatment framework, not rivals to be defeated. The framework they envision integrates behavioral, pharmacological, endoscopic, and surgical interventions, matched to disease stage and adapted over time. A patient might begin with structured lifestyle change and medication, add an endoscopic or pharmacological escalation if response is inadequate, and proceed to surgery when clinical obesity is established or when pharmacotherapy fails, is not tolerated, or is discontinued. Surgery, in this model, is not the option of last resort after everything else has failed, nor the reflexive first move. It is one instrument in a staged repertoire, deployed according to disease severity and patient goals.

The real-world behavior of patients on the new drugs adds urgency to this reasoning. A 2025 analysis in JAMA Network Open tracked discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among United States adults with overweight or obesity and documented substantial rates of patients stopping their medication, a pattern consistent with the well-known challenges of cost, supply, side effects, and waning motivation that accompany chronic injectable therapy. Weight regain after discontinuation is a predictable consequence of stopping an appetite-suppressing drug, because the underlying biology of obesity has not changed. The authors point to this fragility of pharmacological maintenance as precisely the scenario in which a durable intervention such as surgery retains its value, either as primary therapy for selected patients or as a rescue strategy after pharmacotherapy-induced weight loss plateaus or reverses. The International Federation for the Surgery of Obesity has already issued a formal statement, co-authored by several of the same authors, addressing how to position surgery after drug-induced weight loss in patients with clinical obesity.

Economics complicates the picture further. Two recent analyses cited in the perspective tackle the cost question directly. A matched cohort study published in Surgery for Obesity and Related Diseases in 2025 examined the cost-effectiveness of bariatric surgery and found grounds for arguing that surgical treatment pays for itself over time through reduced management of diabetes, cardiovascular disease, and other obesity complications. A separate cost comparison in Surgical Endoscopy asked where the break-even point lies between GLP-1 receptor agonists and surgery, a question that becomes pointed when a medication must be taken indefinitely at an annual cost that can exceed the one-time price of an operation within a few years. Health systems cannot fund everything for everyone, and the authors argue that stage-adapted care, in which expensive definitive therapy is reserved for established clinical disease, is the most defensible way to allocate limited resources while still offering earlier, less intensive support to those at risk.

Digital therapeutics form the final piece of the multimodal puzzle. A randomized controlled trial published in the same journal in 2026 evaluated a digital health application for weight management in people with obesity and reported six-month efficacy results, illustrating how digitally enabled care pathways are being woven into the therapeutic landscape alongside drugs and surgery. The authors view these tools not as competitors but as connective tissue: platforms that can extend behavioral support, monitor patients after surgery, flag weight regain, and coordinate escalation between treatment modalities. In an integrated system, a patient’s care might move fluidly between an app, a prescribing physician, an endoscopist, and a surgeon, with each step justified by measured disease status rather than by the habits or incentives of any single specialty.

The perspective’s ultimate message is a call for clinical discipline in a moment of therapeutic enthusiasm. Effective drugs have not made surgery obsolete, and surgery has not made drugs unnecessary; instead, the new diagnostic framework of clinical obesity gives clinicians a principled way to decide which patient needs which tool, and when. Mispositioning surgery, the authors warn, will delay definitive treatment for the sickest patients, while abandoning pharmacotherapy would deny many others a safer, less invasive path. The task for the coming decade is to build care pathways that treat obesity as the heterogeneous, chronic, progressive disease it is, matching the durability of the scalpel and the flexibility of the syringe to the stage of the disease in front of the clinician. In that matching, the authors conclude, lies the future of obesity medicine.

Subject of Research: Positioning of metabolic bariatric surgery within multimodal obesity care in the era of effective pharmacotherapy

Article Title: Where does surgery fit in the era of effective obesity pharmacotherapy? Positioning metabolic bariatric surgery within multimodal obesity care

Article References: Cohen, R. V., Salminen, P., Ponce, J., & Prager, G. (2026). Where does surgery fit in the era of effective obesity pharmacotherapy? Positioning metabolic bariatric surgery within multimodal obesity care. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02215-y

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02215-y

Keywords: obesity, bariatric surgery, metabolic surgery, GLP-1 receptor agonists, pharmacotherapy, clinical obesity, Lancet Commission, multimodal treatment, digital health, cost-effectiveness, weight regain, International Journal of Obesity

The study, led by Chia Siang Kow and colleagues, took a fresh statistical look at the six clinical studies and ten intervention arms that tracked semaglutide or tirzepatide after treatment discontinuation, drawing on data covering 1776 participants. Rather than relying on simple pooled averages, the researchers reconstructed the arm-level data and applied a Bayesian hierarchical longitudinal model, a statistical framework that jointly models repeated measurements over time while explicitly accounting for variability between study arms. This approach allowed the team to go beyond asking how many kilograms are regained each month and instead translate the trajectory into clinically meaningful milestones, complete with full probability distributions that quantify uncertainty.

The headline finding is that people who stop taking these medications regain an estimated 1.04 kilograms per month on average, with a 95 percent credible interval of 0.80 to 1.29 kilograms per month. The modelled average participant had lost 15.35 kilograms by the time treatment ended. Under the linear model assumed by the researchers, half of that hard-won loss was projected to return within about 7.5 months, and participants were projected to be back at their baseline weight by roughly 15 months after stopping. In practical terms, the clock on the treatment’s benefits starts ticking almost the moment the final injection wears off.

The month-by-month trajectory is particularly striking. Within the follow-up window actually observed in the trials, which extended to 52 weeks, the modelled average weight change was still below baseline at six months, at minus 9.12 kilograms, but by then approximately 41 percent of the initial weight loss had already been regained. At nine months the average was minus 6.01 kilograms, corresponding to 62 percent regained, and by twelve months the average stood at minus 2.90 kilograms, meaning roughly 83 percent of the lost weight had returned. The posterior probability that the average trajectory had regained at least half of the initial weight loss climbed from just 12.5 percent at six months to 86.7 percent at nine months and a near-certain 99.5 percent at one year.

It is important to understand the mathematical machinery behind these numbers. The researchers assumed a constant linear regain slope rather than a curving trajectory, a choice justified because follow-up data were sparse and a prior systematic review had found that adding a nonlinear term did not improve model fit. Each study arm was treated as a repeated-measures trajectory with its own random effects for both the weight loss present at discontinuation and the subsequent regain rate. The Bayesian estimation relied on full Markov chain Monte Carlo sampling, with convergence confirmed by R-hat statistics hovering at approximately 1.00 and large effective sample sizes for the key slope parameters. Estimates extending beyond the maximum observed follow-up of 52 weeks, including the projected return to baseline at 15 months, are explicitly flagged as extrapolations of the average trajectory rather than directly observed outcomes.

One of the most provocative aspects of the analysis is its comparison of the two drugs. Tirzepatide arms showed a numerically faster unadjusted regain rate of 1.10 kilograms per month compared with 0.89 kilograms per month for semaglutide, and projected return to baseline was correspondingly sooner, at roughly 14.5 months versus 17.3 months. But when the researchers adjusted for the magnitude of initial weight loss and post-discontinuation support in a Bayesian meta-regression, the drug difference essentially vanished. The adjusted effect of tirzepatide versus semaglutide was a negligible minus 0.04 kilograms per month, with a posterior probability of only 40.2 percent that tirzepatide regains faster. In other words, the apparent difference in rebound between the two drugs likely reflects differences in how much weight was lost in the first place, not any inherent difference in the physiology of regain.

That observation points to one of the study’s most interesting exploratory findings: greater initial weight loss was itself the strongest directional predictor of faster absolute regain. Each additional 5 kilograms of weight lost during treatment was associated with a 0.20 kilograms per month faster regain slope, a result carrying a 92.1 percent posterior probability, though the credible interval included zero. The authors caution that this association may partly reflect mathematical coupling, since a larger initial loss simply creates more opportunity for absolute regain. Meanwhile, behavioural or lifestyle support after discontinuation showed a directional association with slower regain, an estimated effect of minus 0.19 kilograms per month with an 87.2 percent probability of benefit, but the imprecise estimate means the finding remains inconclusive. With only ten intervention arms available, all meta-regression results are explicitly exploratory and hypothesis-generating rather than definitive.

Sensitivity analyses reinforced the robustness of the core conclusion. A contrast analysis using the randomised differences between intervention and control arms showed a similar direction of effect, though with less precision. A post hoc analysis excluded the three SURPASS-1 arms, which came from a trial of adults with Type 2 diabetes receiving tirzepatide as glucose-lowering monotherapy rather than for weight management. Excluding those arms left the monthly regain slope essentially unchanged at 0.95 kilograms per month, though the projected time to 50 percent regain lengthened to 9.42 months because the average initial weight loss among the remaining arms was greater. The qualitative message of rapid regain survived every stress test the researchers applied.

The clinical implications are considerable. Because discontinuation is common in routine practice, driven by cost, tolerability problems, access restrictions, treatment fatigue and genuine uncertainty about how long therapy should last, the findings suggest that clinicians should plan proactive monitoring within the first several months after stopping treatment, when early regain can be identified and maintenance strategies reassessed. The authors are careful to note that their data do not determine whether dose tapering, lower-dose maintenance, drug switching, intermittent treatment or any specific behavioural programme can prevent regain; those questions require dedicated trials. They also stress that the analysis captured body-weight trajectories only, so any statements about cardiometabolic benefits, cost-effectiveness or the consequences of fixed-duration treatment policies remain hypotheses informed by the weight pattern rather than direct findings.

What the study ultimately delivers is a statistically rigorous quantification of something patients and clinicians have long suspected: incretin-based anti-obesity medications suppress appetite and enable weight loss while they are active, and withdrawing that physiological support removes the very mechanism holding the weight down. Between-study heterogeneity was real but moderate, with a between-arm standard deviation of 6.78 kilograms for initial weight loss and 0.26 kilograms per month for the regain slope, suggesting that while individual experiences vary, the average trajectory is consistently steep. As these drugs reshape obesity medicine and public expectations, the analysis argues that their long-term value must be judged not only by the dramatic losses achieved during treatment but by an honest accounting of what follows when the treatment ends, and by research that extends follow-up beyond one year, reports regain in both absolute and percentage terms, and directly tests the maintenance strategies that patients will increasingly demand.

Subject of Research: Weight regain after discontinuation of the incretin-based anti-obesity medications semaglutide and tirzepatide

Article Title: Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Article References: Kow, C. S., Thiruchelvam, K., Ramachandram, D. S., & Zaihan, A. F. (2026). Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5), Article e70325. https://doi.org/10.1002/edm2.70325

Image Credits: AI Generated

DOI: 10.1002/edm2.70325

Keywords: semaglutide, tirzepatide, weight regain, obesity, incretin therapies, GLP-1 receptor agonists, Bayesian meta-analysis, treatment discontinuation, weight loss maintenance, anti-obesity pharmacotherapy, Weight, Regain